We serve Chemical Name:Lumiflavine CAS:1088-56-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:Lumiflavine
CAS.NO:1088-56-8
Synonyms:7,8,10-Trimethylbenzo[g]pteridine-2,4(3H,10H)-dione;Benzo[g]pteridine-2,4(3H,10H)-dione, 7,8,10-trimethyl-;7,8,10-trimethyl-10H-benzo[g]pteridine-2,4-dione;Lumilactoflavin;7,8,10-Trimethyl-10H-benzo[g]pteridin-2,4-dion;Lumiflavin;7,8,10-Trimethylisoalloxazine;7,8,10-Trimethylbenzo(g)pteridine-2,4(3H,10H)-dione;EINECS 214-125-5;Lumiflavine;7,8,10-trimethylbenzo[g]pteridine-2,4-dione;MFCD00042742
Molecular Formula:C13H12N4O2
Molecular Weight:256.260
HS Code:2933990090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:1.5±0.1 g/cm3
Index of Refraction:1.729
PSA:80.64000
Exact Mass:256.096039
LogP:0.23
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 7,8,10-Trimethylbenzo[g]pteridine-2,4(3H,10H)-dione chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD00042742 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,7,8,10-Trimethylbenzo[g]pteridine-2,4(3H,10H)-dione Use and application,7,8,10-trimethyl-10H-benzo[g]pteridine-2,4-dione technical grade,usp/ep/jp grade.
Related News: Analysts at Mizuho Americas, who spoke to Lilly’s management this week, said that may well have now changed. “Overall, it sounds like the approval raises new questions for Lilly (as it does for many of us!),” the firm said in a note to clients. Lumiflavine manufacturer The API can be directly formulated, and the intermediate can only be used to synthesize the next product. Only through the intermediate can the API be manufactured. Lumiflavine supplier Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. Lumiflavine vendor Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. Lumiflavine factory Analysts at Mizuho Americas, who spoke to Lilly’s management this week, said that may well have now changed. “Overall, it sounds like the approval raises new questions for Lilly (as it does for many of us!),” the firm said in a note to clients.
